GCP
WHWK

GSA Capital Partners’s Whitehawk Therapeutics WHWK Stock Holding History

GSA Capital Partners’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-21,097
Closed -$43K – 2102
2024
Q3 		$43K Sell
21,097
-6,392
-23% -$10.3K ﹤0.01% 1525
2024
Q2 		$40K Buy
+27,489
New +$50.9K ﹤0.01% 1567
2021
Q1 		– Sell
-1,193
Closed -$18K – 1559
2020
Q4 		$18K Buy
+1,193
New +$25.5K ﹤0.01% 1150

Other funds holding WHWK

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

GSA Capital Partners's WHWK Position: Q4 2024 in Review

GSA Capital Partners sold out of Whitehawk Therapeutics (WHWK) in Q4 2024, closing a stake of 21,097 shares — an estimated $43K sold.

GSA Capital Partners first reported a position in WHWK in Q4 2020 and held it in 3 quarters. The position peaked at $43K in Q3 2024. 53 funds tracked by Wall St. Rank hold WHWK as of Q4 2024.

  • GSA Capital Partners reported no remaining Whitehawk Therapeutics position as of Q4 2024 after selling out during the quarter.
  • GSA Capital Partners sold 21,097 Whitehawk Therapeutics shares in Q4 2024, an estimated $43K.
  • GSA Capital Partners first reported a position in Whitehawk Therapeutics in Q4 2020 and held it in 3 quarters.
  • GSA Capital Partners's Whitehawk Therapeutics position peaked at $43K in Q3 2024.
  • 53 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q4 2024.

Based on GSA Capital Partners's 13F filing for Q4 2024, filed 7 Feb 2025.